期刊
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
卷 16, 期 6, 页码 457-461出版社
ADIS INT LTD
DOI: 10.1007/s40257-015-0156-2
关键词
-
类别
资金
- Bayer
- Galderma
Rosacea is a common chronic inflammatory disorder that affects approximately 16 million Americans. The multifactorial pathophysiology of rosacea is not fully understood. Several new treatment options were recently US Food and Drug Administration approved or are in clinical trials. This paper reviews new treatment options including ivermectin, brimonidine, the new foam formulation of azelaic acid, and oxymetazoline. The potential role in therapy, patient selection, and adverse effects of these agents are discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据